Nothing Special   »   [go: up one dir, main page]

FI108611B - Menetelmä mikropartikkelien valmistamiseksi - Google Patents

Menetelmä mikropartikkelien valmistamiseksi Download PDF

Info

Publication number
FI108611B
FI108611B FI903429A FI903429A FI108611B FI 108611 B FI108611 B FI 108611B FI 903429 A FI903429 A FI 903429A FI 903429 A FI903429 A FI 903429A FI 108611 B FI108611 B FI 108611B
Authority
FI
Finland
Prior art keywords
water
drug
microparticles
emulsion
polymer
Prior art date
Application number
FI903429A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI903429A0 (fi
Inventor
Thomas Kissel
David Bodmer
Jones Wing Fong
Hawkins Valliant Maulding
Oskar Nagele
Jane Edna Pearson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of FI903429A0 publication Critical patent/FI903429A0/fi
Priority to FI991120A priority Critical patent/FI106926B/fi
Application granted granted Critical
Publication of FI108611B publication Critical patent/FI108611B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI903429A 1989-07-07 1990-07-06 Menetelmä mikropartikkelien valmistamiseksi FI108611B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI991120A FI106926B (fi) 1989-07-07 1999-05-17 Menetelmä pitkäaikaisesti vapautuvan koostumuksen muodostamiseksi

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37702389A 1989-07-07 1989-07-07
US37702389 1989-07-07
US41134789A 1989-09-22 1989-09-22
US41134789 1989-09-22

Publications (2)

Publication Number Publication Date
FI903429A0 FI903429A0 (fi) 1990-07-06
FI108611B true FI108611B (fi) 2002-02-28

Family

ID=27007654

Family Applications (3)

Application Number Title Priority Date Filing Date
FI903429A FI108611B (fi) 1989-07-07 1990-07-06 Menetelmä mikropartikkelien valmistamiseksi
FI20000059A FI109543B (fi) 1989-07-07 2000-01-12 Menetelmä terapeuttisesti käyttökelpoisen oktreotidipamoaatin valmistamiseksi
FI20000060A FI109334B (fi) 1989-07-07 2000-01-12 Menetelmä pitkäaikaisesti vapautuvan koostumuksen muodostamiseksi

Family Applications After (2)

Application Number Title Priority Date Filing Date
FI20000059A FI109543B (fi) 1989-07-07 2000-01-12 Menetelmä terapeuttisesti käyttökelpoisen oktreotidipamoaatin valmistamiseksi
FI20000060A FI109334B (fi) 1989-07-07 2000-01-12 Menetelmä pitkäaikaisesti vapautuvan koostumuksen muodostamiseksi

Country Status (27)

Country Link
JP (5) JPH0832624B2 (de)
KR (2) KR100303681B1 (de)
AT (1) AT406225B (de)
AU (2) AU641407B2 (de)
BE (1) BE1004486A3 (de)
CA (1) CA2020477C (de)
CH (1) CH685230A5 (de)
CY (1) CY1965A (de)
DE (2) DE4042752B4 (de)
DK (1) DK175849B1 (de)
FI (3) FI108611B (de)
FR (1) FR2649319A1 (de)
GB (2) GB2234896B (de)
GR (1) GR1001121B (de)
HK (2) HK97695A (de)
HU (2) HU221294B1 (de)
IE (2) IE64411B1 (de)
IL (3) IL94983A (de)
IT (1) IT1241460B (de)
LU (1) LU87764A1 (de)
MY (1) MY106722A (de)
NL (1) NL195027C (de)
NO (2) NO302928B1 (de)
NZ (1) NZ234384A (de)
PT (1) PT94628B (de)
SE (1) SE512992C2 (de)
SG (1) SG26416G (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
DE4218510A1 (de) * 1992-06-02 1993-12-09 Pharmatech Gmbh Verfahren zur Herstellung biologisch abbaubarer Polyester
AU4198793A (en) † 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
EP0626170A3 (de) * 1993-05-10 1996-03-27 Sandoz Ltd Stabilisierung pharmakologisch aktiver Verbindungen in Mitteln mit verzögerter Freisetzung.
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
GB9310781D0 (en) * 1993-05-25 1993-07-14 Davis Stanley S Preparation of microparticles
WO1995013814A1 (en) 1993-11-19 1995-05-26 Janssen Pharmaceutica N.V. Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
JP2000500744A (ja) 1995-11-09 2000-01-25 マイクロバイオロジカル リサーチ オーソリティー ワクチン接種および遺伝子治療のためのマイクロカプセル化ｄｎａ
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9810236D0 (en) * 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US7107268B1 (en) 1998-11-12 2006-09-12 Printable Technologies, Inc. Centralized system and method for managing enterprise operations
US6226656B1 (en) 1998-11-12 2001-05-01 Sourcefinder, Inc. System and method for creating, generating and processing user-defined generic specs
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
EP1044683A1 (de) * 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. Einschrittdispersionsverfahren zur Mikroverkapselung von wasserlöslichen Substanzen
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100392501B1 (ko) * 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7252842B2 (en) 2000-12-21 2007-08-07 Alrise Biosystems Gmbh Induced phase transition method for the production of microparticles containing hydrophilic active agents
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
EP2462923A3 (de) * 2003-07-18 2012-08-29 Oakwood Laboratories L.L.C. Vorbeugung der Reduzierung des Molekulargewichts, der Bildung von Verunreinigungen und der Gelbildung in Polymerzusammensetzungen
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
WO2005082405A1 (ja) * 2004-02-26 2005-09-09 Japan Science And Technology Agency たんぱく性薬物の注射用徐放性微粒子製剤およびその製造法
DE102004053373A1 (de) * 2004-11-02 2006-05-04 Justus-Liebig-Universität Giessen Erfindung betreffend anisometrische Partikel in Form von Nano-/Meso-Fasern -Röhren, -Kabeln -Bändern und deren gekrümmte oder verzweigte Abwandlungen
KR100741867B1 (ko) * 2005-07-05 2007-07-24 전북대학교산학협력단 수중유적 및 용매 증발법을 이용한 이중층 미립구의제조방법
BRPI0620063B8 (pt) * 2005-12-22 2021-05-25 Novartis Ag composição farmacêutica de liberação sustentada na forma de micropartículas, uso, e kit de administração
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
AU2009209594A1 (en) 2008-01-30 2009-08-06 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP2621473A2 (de) * 2010-09-30 2013-08-07 Evonik Corporation Verfahren zur beseitigung von organischen lösungsmittelresten von mikropartikeln
CN103298453A (zh) * 2010-09-30 2013-09-11 赢创有限公司 制备低残留溶剂微粒的乳化法
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
KR102464650B1 (ko) 2016-05-03 2022-11-10 엘에스일렉트릭(주) 배선용 차단기의 한류장치
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH649217A5 (de) * 1977-08-25 1985-05-15 Sandoz Ag Bromocriptin enthaltende mikrokapseln.
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
DE19375086I2 (de) * 1979-11-27 2003-01-09 Novartis Ag Polypeptide Verfahren zu ihrer Herstellung pharmazeutische Zusammensetzungen die diese Polypeptide enthalten und ihre Verwendung
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US4485101A (en) * 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
JPH0657658B2 (ja) * 1985-04-11 1994-08-03 住友製薬株式会社 徐放性製剤
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8331158D0 (en) * 1983-11-22 1983-12-29 British Telecomm Metal/semiconductor deposition
JPS60181029A (ja) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd 徐放性製剤の製法
CH660302A5 (fr) * 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
ATE61935T1 (de) * 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
CH665558A5 (en) * 1985-10-09 1988-05-31 Debiopharm Sa Phase sepn. prodn. of microcapsules for water soluble pharmaceuticals - using fluoro-substd. aliphatic hydrocarbon as non-solvent in the hardening stage
JP2539789B2 (ja) * 1986-03-06 1996-10-02 日本原子力研究所 ポリラクトンからなる徐放性薬物複合体の製造方法
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH672887A5 (de) * 1987-10-14 1990-01-15 Debiopharm Sa
DE3738228A1 (de) * 1987-11-11 1989-05-24 Hoechst Ag Verfahren zur herstellung von bioabbaubaren mikrokapseln wasserloeslicher peptide und proteine sowie nach diesem verfahren erhaltene mikrokapseln
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル

Also Published As

Publication number Publication date
DK175849B1 (da) 2005-03-29
ATA144090A (de) 1999-08-15
JP2001233897A (ja) 2001-08-28
HU221294B1 (en) 2002-09-28
HUT54037A (en) 1991-01-28
FI109334B (fi) 2002-07-15
CA2020477A1 (en) 1991-01-08
NL195027B (nl) 2003-08-01
DK162590A (da) 1991-01-08
JPH0832624B2 (ja) 1996-03-29
AT406225B (de) 2000-03-27
JPH07309897A (ja) 1995-11-28
AU641407B2 (en) 1993-09-23
FI20000059A (fi) 2000-01-12
NO903001L (no) 1991-01-08
AU5874690A (en) 1991-01-10
HU903974D0 (en) 1990-11-28
DE4021517B4 (de) 2009-04-09
CY1965A (en) 1997-07-04
CA2020477C (en) 2000-11-21
HK97695A (en) 1995-06-23
LU87764A1 (fr) 1992-03-11
NO302928B1 (no) 1998-05-11
AU2332195A (en) 1995-09-07
KR100303681B1 (ko) 2002-05-16
GB2234896B (en) 1994-01-19
KR910002430A (ko) 1991-02-25
JPH08198771A (ja) 1996-08-06
JPH0368511A (ja) 1991-03-25
MY106722A (en) 1995-07-31
SG26416G (en) 1995-09-01
SE512992C2 (sv) 2000-06-12
GB9306204D0 (en) 1993-05-19
BE1004486A3 (fr) 1992-12-01
DK162590D0 (da) 1990-07-05
GR1001121B (el) 1993-04-28
JP2931773B2 (ja) 1999-08-09
PT94628B (pt) 1997-06-30
IL94983A0 (en) 1991-06-10
NO320444B1 (no) 2005-12-05
IL131880A (en) 2001-12-23
GR900100513A (en) 1991-12-10
GB9014704D0 (en) 1990-08-22
HK197496A (en) 1996-11-08
KR100442931B1 (ko) 2004-08-02
GB2265311B (en) 1994-02-09
FR2649319A1 (fr) 1991-01-11
SE9002364L (sv) 1991-01-08
CH685230A5 (de) 1995-05-15
FI20000060A (fi) 2000-01-12
DE4042752B4 (de) 2009-05-07
IT9048113A1 (it) 1992-01-05
NO903001D0 (no) 1990-07-05
IT9048113A0 (it) 1990-07-05
NO983923L (no) 1991-01-08
FI903429A0 (fi) 1990-07-06
FI109543B (fi) 2002-08-30
GB2234896A (en) 1991-02-20
FR2649319B1 (de) 1994-12-09
NO983923D0 (no) 1998-08-26
IT1241460B (it) 1994-01-17
IE902435A1 (en) 1991-02-13
IL94983A (en) 1999-08-17
NL9001537A (nl) 1991-02-01
IL131881A (en) 2001-12-23
DE4021517A1 (de) 1991-01-17
SE9002364D0 (sv) 1990-07-05
IE64216B1 (en) 1995-07-26
PT94628A (pt) 1991-03-20
NZ234384A (en) 1994-05-26
GB2265311A (en) 1993-09-29
AU687553B2 (en) 1998-02-26
NL195027C (nl) 2003-12-02
IE64411B1 (en) 1995-08-09
HU211602A9 (en) 1995-12-28
JPH07285853A (ja) 1995-10-31

Similar Documents

Publication Publication Date Title
FI108611B (fi) Menetelmä mikropartikkelien valmistamiseksi
US5538739A (en) Sustained release formulations of water soluble peptides
US5639480A (en) Sustained release formulations of water soluble peptides
US4675189A (en) Microencapsulation of water soluble active polypeptides
EP2331075B1 (de) Peptidformulierungen mit gesteuerter freisetzung
CA2316052C (en) Sustained release formulations of water soluble peptides
FI106926B (fi) Menetelmä pitkäaikaisesti vapautuvan koostumuksen muodostamiseksi
CA2535463A1 (en) Octreotide-pamoate and its use in sustained release formulations of water soluble peptides
NL195090C (nl) Preparaten van in water oplosbare peptiden met een langzame afgifte.
IL112286A (en) Process for the production of a microparticle and microparticle obtained thereby
SA90110050B1 (ar) مستحضرات ممتدة المفعول لببتيدات تذوب في الماء
CH686252A5 (de) Octreotidepamoat und dessen Verwendung zur Herstellung von pharmazeutischen Formulierungen.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

FG Patent granted

Owner name: NOVARTIS AG